Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1936 1
1946 1
1949 1
1951 1
1955 1
1961 1
1962 1
1963 2
1964 2
1965 2
1967 1
1968 1
1969 1
1970 1
1971 3
1972 3
1973 1
1974 1
1975 2
1976 2
1983 1
1985 1
1986 2
1987 1
1989 2
1991 4
1992 4
1993 1
1994 4
1996 2
1997 1
1998 3
2001 1
2003 1
2004 1
2005 2
2006 2
2007 10
2008 12
2009 8
2010 8
2011 2
2012 4
2013 6
2014 4
2015 6
2016 10
2017 10
2018 9
2019 19
2020 11
2021 24
2022 28
2023 27
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Results by year

Filters applied: . Clear all
Page 1
A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement.
Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, MacKinnon DP, Mansell G, Collins GS, Golub RM, McAuley JH; AGReMA group; Localio AR, van Amelsvoort L, Guallar E, Rijnhart J, Goldsmith K, Fairchild AJ, Lewis CC, Kamper SJ, Williams CM, Henschke N. Lee H, et al. Among authors: goldsmith k. JAMA. 2021 Sep 21;326(11):1045-1056. doi: 10.1001/jama.2021.14075. JAMA. 2021. PMID: 34546296 Free PMC article.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Goldsmith KC, et al. Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012551 Free PMC article. Clinical Trial.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. Bakouny Z, et al. JAMA Oncol. 2023 Jan 1;9(1):128-134. doi: 10.1001/jamaoncol.2022.5357. JAMA Oncol. 2023. PMID: 36326731 Free PMC article.
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP. Berko ER, et al. Among authors: goldsmith kc. Nat Commun. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0. Nat Commun. 2023. PMID: 37147298 Free PMC article.
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Bagatell R, DuBois SG, Naranjo A, Belle J, Goldsmith KC, Park JR, Irwin MS; COG Neuroblastoma Committee. Bagatell R, et al. Among authors: goldsmith kc. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30572. doi: 10.1002/pbc.30572. Epub 2023 Jul 17. Pediatr Blood Cancer. 2023. PMID: 37458162
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP; COVID-19 and Cancer Consortium (CCC19). Fu J, et al. JAMA Netw Open. 2022 Mar 1;5(3):e224304. doi: 10.1001/jamanetworkopen.2022.4304. JAMA Netw Open. 2022. PMID: 35344045 Free PMC article.
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma.
Lee JY, Jonus HC, Sadanand A, Branella GM, Maximov V, Suttapitugsakul S, Schniederjan MJ, Shim J, Ho A, Parwani KK, Fedanov A, Pilgrim AA, Silva JA, Schnepp RW, Doering CB, Wu R, Spencer HT, Goldsmith KC. Lee JY, et al. Among authors: goldsmith kc. Cell Rep Med. 2023 Jun 20;4(6):101091. doi: 10.1016/j.xcrm.2023.101091. Cell Rep Med. 2023. PMID: 37343516 Free PMC article.
237 results